A similar trend was seen among patients treated with aflibercept every eight weeks in the “VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD” studies (VIEW 1 and VIEW 2), which was concluded to be secondary to inadequate frequency of administration [20]. This evidence concerns the gene VEGFA and age-related macular degeneration.